Dr Tirzepatide

What Is Tirzepatide? The Dual GIP/GLP-1 Peptide Explained

The short version

What is tirzepatide? It is a prescription medicine approved by the FDA for type 2 diabetes and obesity. Structurally, it is a synthetic peptide — a short chain of amino acids (the building blocks of proteins) — engineered to activate two gut-hormone receptors at the same time: the GIP receptor and the GLP-1 receptor. Both receptors respond to hormones the gut normally releases after meals to help regulate blood sugar and appetite. By activating both with one weekly injection, tirzepatide produces effects on blood sugar control and body weight that are larger in trials than activating either receptor alone.

What is tirzepatide: structure and classification

Tirzepatide is a 39-amino-acid synthetic peptide built on the backbone of native GIP (glucose-dependent insulinotropic polypeptide — a hormone secreted from gut cells after meals that stimulates insulin release). Its molecular formula is C₂₂₅H₃₄₈N₄₈O₆₈, molecular weight 4,813.53 Da (CAS 2023788-19-2, ATC A10BX16).

The structure differs from native GIP in two critical ways. First, several amino acids in the sequence are modified to enable it to activate both GIP and GLP-1 receptors (glucagon-like peptide-1, a second gut incretin hormone). Second, a C20 fatty diacid (a lipid tail) is attached via a glutamic acid linker and two AEEA spacer units to a lysine at position 20 in the chain. This lipid arm binds the peptide to serum albumin (the most abundant protein in blood), dramatically slowing its clearance from the body and giving it a half-life of approximately five days — sufficient to maintain steady blood levels with once-weekly dosing [1][7].

It is classified as a dual GIP and GLP-1 receptor agonist (a molecule that activates these receptors), also informally called a 'twincretin' or 'dual incretin mimetic.' The INN (International Nonproprietary Name) is 'tirzepatide.' Its development code was LY3298176.

Tirzepatide mechanism of action: two receptors, one molecule

Tirzepatide mechanism of action rests on the simultaneous activation of two incretin hormone receptors.

GLP-1 receptor (GLP-1R) activation: GLP-1 (glucagon-like peptide-1) is released by intestinal L-cells in response to food. It stimulates insulin secretion from the pancreas in a glucose-dependent fashion (meaning it only stimulates insulin when blood glucose is elevated, reducing hypoglycaemia risk), suppresses glucagon (a pancreatic hormone that raises blood glucose), delays gastric emptying, and acts in the hypothalamus to suppress appetite [1][2].

GIP receptor (GIPR) activation: GIP (glucose-dependent insulinotropic polypeptide) is released by intestinal K-cells after meals. It enhances insulin secretion from the pancreas, and in adipose (fat) tissue it promotes fat storage at physiological levels — but at pharmacological doses, its interaction with GLP-1 receptor co-activation appears to enhance the net metabolic effect [1].

In vitro characterisation found tirzepatide engages the GIP receptor to a greater degree than the GLP-1 receptor (an 'imbalanced' dual agonist) and shows biased GLP-1 receptor signalling: it preferentially activates the cAMP intracellular pathway over beta-arrestin recruitment. Because beta-arrestin1 normally limits the insulin-secretory response to GLP-1, this biased engagement may enhance insulin secretion [2].

The combined effect — larger glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and appetite reduction — appears to produce greater glycaemic and weight effects than selective GLP-1 receptor agonism alone, as demonstrated in head-to-head trials [3][5].

Approved indications and regulatory record

Tirzepatide is FDA-approved for three indications:

  1. Type 2 diabetes mellitus (May 2022): as an adjunct to diet and exercise in adults [18]. It is not approved for type 1 diabetes.
  1. Chronic weight management (November 2023): in adults with BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related condition such as hypertension, dyslipidaemia (abnormal blood fat levels), or obstructive sleep apnea [9].
  1. Moderate-to-severe obstructive sleep apnea in adults with obesity: supported by the SURMOUNT-OSA trial, which documented AHI (apnea-hypopnea index — breathing interruptions per hour of sleep) reductions alongside weight reduction [12].

The FDA label states the drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma (a type of thyroid cancer) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2), due to a boxed warning based on rodent carcinogenicity data [18]. The label also notes that it is not indicated for type 1 diabetes.

For the full Tirzepatide references list, see the citations page.

How tirzepatide differs from GLP-1-only agents

Several approved medicines activate only the GLP-1 receptor. Tirzepatide adds GIP receptor activation.

The clinical consequence of adding GIP receptor agonism has been examined in head-to-head trials. SURPASS-2 (n=1,879, type 2 diabetes, 40 weeks) found tirzepatide superior to a selective GLP-1 receptor agonist at all three tested doses on both HbA1c and body weight [3]. SURMOUNT-5 (n=751, obesity without type 2 diabetes, 72 weeks) found tirzepatide producing -20.2% body weight versus -13.7% with maximum-tolerated semaglutide [5].

The pharmacological distinction: tirzepatide is an 'imbalanced' dual agonist, engaging the GIP receptor more fully than the GLP-1 receptor, and shows biased GLP-1R signalling. Whether the GIP receptor engagement is the primary driver of the incremental efficacy, and the mechanism by which it operates, remains an area of active research [2].

In terms of tolerability, a meta-analysis of three head-to-head trials against another approved incretin found discontinuation due to adverse events approximately 32% higher with tirzepatide, driven by GI effects [33]. The greater efficacy and the tolerability profile are the two defining characteristics of the dual-agonism approach.